heart improvement trials featuring msb, page-6

Hi Gardner - keep up the good posts.

As noted in your post ( Oct 11) my understanding is TEVA will close out the CEPH transaction in 4th Qrt ( US financial/calender yr) and TEVA/CEPH will report as a single entity moving forward.

It will be interesting to see how TEVA ($40bn+ company post CEPH) will add to the developement of the MSB pipeline.
It is well known ( noted in TEVA's Goldman Sachs presentation back in June 11) that they are excited by the potential of Revascor ( MSB Cadiovascular Franchise ).

Also as already noted by Vinn on a prior post, what an accolade for MSB (the company and its mangement) to be given centre stage at North Americas premiere Heart convention.

Hand clapping and applause to the MSB management - just for this moment alone with many people to benefit from their innovation and the MPC technology.

Cheers,